ZMYND15 and neoplasm: Taken together, five tumor antigens (ALOX15B, HS3ST2, PIGR, ZMYND15, and LIMK1), with potentially provocative effects on immunological functions, were identified and considered as eligible candidates for anti-PRCC mRNA vaccine development.